Adaptimmune Therapeutics Plc (ADAP) — Working Capital to Net Assets Ratio
Adaptimmune Therapeutics Plc (ADAP) has a Working Capital to Net Assets ratio of -37.5% as of June 2025. Working capital of $26.60 Million (current assets of $78.11 Million minus current liabilities of $51.51 Million) is measured against net assets of $-70.96 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See debt-free asset ratio of Adaptimmune Therapeutics Plc to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Adaptimmune Therapeutics Plc Working Capital to Net Assets (2011–2024)
This chart shows how Adaptimmune Therapeutics Plc's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of June 2025, the ratio stands at -37.5%, reflecting working capital of $26.60 Million against net assets of $-70.96 Million USD. Check Adaptimmune Therapeutics Plc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Adaptimmune Therapeutics Plc (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Adaptimmune Therapeutics Plc from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Adaptimmune Therapeutics Plc stock valuation.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 1043.5% | $123.64 Million | $11.85 Million | $188.17 Million | $64.53 Million | ▲ +702.4 pp |
| 2023 | 341.1% | $134.76 Million | $39.51 Million | $207.55 Million | $72.79 Million | ▲ +107.9 pp |
| 2022 | 233.1% | $190.87 Million | $81.88 Million | $255.37 Million | $64.50 Million | ▲ +61.8 pp |
| 2021 | 171.4% | $352.92 Million | $205.96 Million | $415.46 Million | $62.54 Million | ▲ +66.1 pp |
| 2020 | 105.2% | $359.08 Million | $341.23 Million | $398.15 Million | $39.07 Million | ▲ +35.6 pp |
| 2019 | 69.7% | $86.15 Million | $123.64 Million | $120.49 Million | $34.34 Million | ▼ -14.0 pp |
| 2018 | 83.7% | $206.66 Million | $246.88 Million | $231.09 Million | $24.44 Million | ▲ +6.9 pp |
| 2017 | 76.8% | $155.87 Million | $202.98 Million | $230.18 Million | $74.31 Million | ▼ -18.6 pp |
| 2016 | 95.4% | $158.48 Million | $166.14 Million | $198.75 Million | $40.27 Million | ▼ -8.0 pp |
| 2015 | 103.4% | $268.35 Million | $259.61 Million | $295.11 Million | $26.76 Million | ▲ +0.0 pp |
| 2014 | 103.4% | $268.35 Million | $259.61 Million | $295.11 Million | $26.76 Million | ▲ +62.7 pp |
| 2013 | 40.6% | $979.32K | $2.41 Million | $54.09 Million | $53.11 Million | ▼ -69.0 pp |
| 2012 | 109.7% | $-2.36 Million | $-2.16 Million | $1.60 Million | $3.97 Million | ▼ -67.8 pp |
| 2011 | 177.5% | $-223.04K | $-125.66K | $3.87 Million | $4.09 Million | — |